#immunotherapy

#immunotherapy

The pilot program aims to enhance early detection and treatment of lung cancer in Ireland through innovative screening methods.

Discovery of HDAC3's role in regulating immune response to KRAS-driven lung cancer indicates potential for new therapeutic approaches.

The world's first mRNA lung cancer vaccine, BNT116, shows promise in treating non-small cell lung cancer and improving survival rates.

Miriam Staunton is advocating for better access to cancer treatments and trials based on her personal experience with melanoma.

Breast cancer vaccines are in development, focusing on treating advanced cases and possibly preventing recurrence.

Therapeutic T cells used for AML may impair their own effectiveness through secreted proteins.

B-cell therapy may offer a new, promising approach to treating glioblastoma.

Immunotherapy represents a revolutionary advancement in cancer treatment, surpassing traditional methods like chemotherapy and radiotherapy in efficacy.

Pembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.

Lumicks has secured €20mn funding to enhance immunotherapy drug discovery by improving its real-time cell avidity analyser technology.

LUMICKS secures €20M to enhance its innovative cell avidity platform, impacting drug discovery and immunotherapy research.

Immunotherapy has significantly improved prognosis and survival rates for patients with metastatic melanoma over the past 15 years.

NK cells engineered with IL-21 show promising antitumor activity against glioblastoma stem cells, providing a potential new treatment approach.

Personalized treatment based on melanoma research used in a world-first experimental treatment for glioblastoma.

Immunotherapy drug Keytruda could benefit more women with breast cancer

Study suggests Keytruda's effectiveness for different types of breast cancer

Immunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.

Natural killer (NK) cells from umbilical-cord blood show promise as a potentially effective and less side-effect-prone alternative to T-cell therapies for blood cancer treatment.

Daily immunotherapy via dermal patch reduced risks in children with cow's milk allergy.

Immunosuppressants and immunotherapy alone may not prevent organ rejection in kidney transplant recipients with skin cancer.

Transplant recipients face higher risk for skin cancer and limited treatment options due to potential rejection from traditional therapies.

Asymmetric cell division in CARTs influences their functional divergence and has implications for improving CAR T-cell therapy efficacy.

A new experimental therapeutic vaccine shows promise for people with KRAS-mutated pancreatic or colorectal cancer.

The vaccine delivers tumor-targeting molecules directly into the lymph nodes, activating T cells and showing positive results in a phase 1 trial.

Senescent cells are damaged cells that accumulate in the body and contribute to age-related diseases.

Researchers have genetically engineered T cells to target and eliminate senescent cells, resulting in rejuvenation in aged mice and slower aging in young mice.

Targeting TIM3 protein may enhance survival in pediatric brain cancer treatments, specifically low-grade astrocytoma, presenting a potential new therapeutic option.

Combination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.

Personalized cancer vaccines take time to produce, allowing cancer to spread.

CAR-T cell therapy revolutionizes blood cancer treatment by enhancing T-lymphocytes to combat tumors, with potential for wider application beyond hematological cancers.

CAR-T-cell therapy faces FDA investigation for potential link to lymphomas.